
Pharma Business - March 10, 2021
Affibody and Inmagene announce IND Clearance
The US FDA has cleared the novel interleukin-17 (IL-17) blocker izokibep (ABY-035) to proceed to Phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis. “Uveitis is one of the leading causes of blindness worldwide. Through the years, we have learned much about the role of IL-17 in the pathogenesis of non-infectious uveitis; thus, we […]

Agreement - May 15, 2020
Affibody enters partnership with Inmagene
Under the terms of the agreement, Affibody will receive a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in Inmagene’s commercialization territory. Affibody and Inmagene Biopharmaceuticals have announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting […]